Lumos Pharma: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Lumos Pharma (NASDAQ:LUMO) reported Q4 earnings with an EPS of $-1.17, missing estimates by -2.0%. Revenue increased by $314 thousand year-over-year. Despite missing this quarter's earnings estimates, past performance shows a positive trend in share price following earnings beats.
March 07, 2024 | 9:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lumos Pharma reported a Q4 EPS of $-1.17, missing estimates by -2.0%, with a revenue increase of $314K from the previous year.
Missing earnings estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. However, Lumos Pharma's history of share price increase following earnings beats could mitigate the impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100